Literature DB >> 23702565

Results of surgery for high-risk prostate cancer.

Steven Joniau1, Lorenzo Tosco, Alberto Briganti, Thomas Vanden Broeck, Paolo Gontero, R Jeffrey Karnes, Martin Spahn, Hein Van Poppel.   

Abstract

PURPOSE OF REVIEW: Surgery for high-risk prostate cancer (PCa) is applied frequently nowadays. Nevertheless, this approach is still surrounded by many controversies. The present review discusses the most recent literature regarding surgery for high-risk PCa. RECENT
FINDINGS: As there is no standard definition of high-risk PCa, outcome comparison between series and treatment approaches is hampered. Nevertheless, recent radical prostatectomy series have shown excellent cancer-specific survival in patients with high-risk PCa. Even for very-high-risk PCa (cT3b-T4 or any cT, N1), surgery may be applied to highly selected patients as a first step of a multimodality approach. Recent experience with robot-assisted surgery opens new possibilities for a minimally invasive approach in this field.Patient selection for surgery was also addressed in recent studies. Excellent cancer-specific survival is seen when specimen-confined PCa is found at final histopathology; a recently published nomogram enables the prediction of specimen-confined disease. Another issue in high-risk PCa is the impact of age and comorbidities on cancer-specific and overall mortality. In a recent study, it was shown that patients with low comorbidity scores, even when at least 70 years old, had a significant risk of dying from their cancer and may benefit most from a surgical approach. A modified extended pelvic lymphadenectomy template was presented, providing optimal removal of positive lymph nodes.
SUMMARY: Radical prostatectomy with extended pelvic lymphadenectomy delivers very good cancer-related outcomes in high-risk and very-high-risk PCa, often within a multimodal approach. Minimally invasive surgery and improved patient selection will be key to further improve oncological and functional outcomes.

Entities:  

Mesh:

Year:  2013        PMID: 23702565     DOI: 10.1097/MOU.0b013e3283620f60

Source DB:  PubMed          Journal:  Curr Opin Urol        ISSN: 0963-0643            Impact factor:   2.309


  8 in total

1.  Prostate cancer: prediction of node-negative status after radical prostatectomy.

Authors:  Lorenzo Tosco; Steven Joniau
Journal:  Nat Rev Urol       Date:  2013-10-22       Impact factor: 14.432

2.  Comparative effectiveness of radical prostatectomy with adjuvant radiotherapy versus radiotherapy plus androgen deprivation therapy for men with advanced prostate cancer.

Authors:  Thomas L Jang; Neal Patel; Izak Faiena; Kushan D Radadia; Dirk F Moore; Sammy E Elsamra; Eric A Singer; Mark N Stein; James A Eastham; Peter T Scardino; Yong Lin; Isaac Y Kim; Grace L Lu-Yao
Journal:  Cancer       Date:  2018-09-25       Impact factor: 6.860

3.  The accuracy of magnetic resonance imaging in prostate cancer staging: a single-institution experience.

Authors:  S F Oon; S P Power; J S Kelly; V McDermott; P Ryan; P C Ryan
Journal:  Ir J Med Sci       Date:  2014-04-06       Impact factor: 1.568

4.  DNA Methylation-Guided Prediction of Clinical Failure in High-Risk Prostate Cancer.

Authors:  Kirill Litovkin; Aleyde Van Eynde; Steven Joniau; Evelyne Lerut; Annouschka Laenen; Thomas Gevaert; Olivier Gevaert; Martin Spahn; Burkhard Kneitz; Pierre Gramme; Thibault Helleputte; Sofie Isebaert; Karin Haustermans; Mathieu Bollen
Journal:  PLoS One       Date:  2015-06-18       Impact factor: 3.240

Review 5.  Current status of radical prostatectomy for high-risk prostate cancer.

Authors:  Ho Won Kang; Joo Yong Lee; Jong Kyou Kwon; Seong Uk Jeh; Hae Do Jung; Young Deuk Choi
Journal:  Korean J Urol       Date:  2014-10-10

6.  Biochemical recurrence risk factors in surgically treated high and very high-risk prostate tumors.

Authors:  Alfredo Aguilera; Beatriz Bañuelos; Jesús Díez; Jose María Alonso-Dorrego; Jesus Cisneros; Javier Peña
Journal:  Cent European J Urol       Date:  2015-09-26

7.  Is Radical Perineal Prostatectomy a Viable Therapeutic Option for Intermediate- and High-risk Prostate Cancer?

Authors:  Hye Won Lee; Hwang Gyun Jeon; Byong Chang Jeong; Seong Il Seo; Seong Soo Jeon; Hyun Moo Lee; Han Yong Choi
Journal:  J Korean Med Sci       Date:  2015-10-16       Impact factor: 2.153

8.  Favorable outcomes in locally advanced and node positive prostate cancer patients treated with combined pelvic IMRT and androgen deprivation therapy.

Authors:  Wolfgang Lilleby; Amol Narrang; Gunnar Tafjord; Ljiljana Vlatkovic; Kjell Magne Russnes; Andreas Stensvold; Knut Håkon Hole; Phuoc Tran; Karsten Eilertsen
Journal:  Radiat Oncol       Date:  2015-11-17       Impact factor: 3.481

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.